# Hangzhou Yuding Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-yuding-biotechnology-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Series A (Jan 28, 2022)
- Investors on record: 1

## About

Based in Hangzhou, China and founded in 2017, Hangzhou Yuding Biotechnology Co., Ltd. is an innovative in vitro diagnostic reagent research and development and production enterprise that focuses on urological oncology field. The company has international good manufacturing practice (GMP) standard production base and research and development center. The company also was certificated as National High-tech Enterprise. Dr. Jiaoti Huang, the founder of the company, works as director of department of Pathology, Duke University.

The development and clinical validation of urological tumor early diagnostic products of the company have been finished. The company also has cooperation with West China Hospital, Sichuan University, The First Affiliated Hospital, College of Medicine, Zhejiang University, Nanjing Gulou Hospital and other hospitals.

The company plans to focus on clinical trials and registration filings for Class III medical device products, as well as the development of other urological oncology pipeline products and the optimization and upgrading of its core technology platform.

## Funding rounds

- Series A, Jan 28, 2022 — Triwise Capital

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series A